The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer
- PMID: 12148568
- DOI: 10.1080/08977190290031969
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer
Abstract
Vascular endothelial growth factor-D (VEGF-D) promotes angiogenesis, lymphangiogenesis and metastatic spread via the lymphatics, however, the mode of VEGF-D action (e.g. paracrine vs. autocrine) was unknown. We analyzed VEGF-D action in human tumors and a mouse model of metastasis. VEGF-D was localized in tumor cells and endothelium in human non-small cell lung carcinoma and breast ductal carcinoma in situ. Tumor vessels positive for VEGF-D were also positive for its receptors, VEGF receptor-2 (VEGFR-2) and/or VEGFR-3 but negative for VEGF-D mRNA, indicating that VEGF-D is secreted by tumor cells and subsequently associates with endothelium via receptor-mediated uptake. The mature form of VEGF-D was detected in tumors demonstrating that VEGF-D is proteolytically processed and bioactive. In a mouse model of metastasis, VEGF-D synthesized in tumor cells became localized on the endothelium and thereby promoted metastatic spread. These data indicate that VEGF-D promotes tumor angiogenesis, lymphangiogenesis and metastatic spread by a paracrine mechanism.
Similar articles
-
Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.J Biol Chem. 2016 Dec 30;291(53):27265-27278. doi: 10.1074/jbc.M116.736801. Epub 2016 Nov 16. J Biol Chem. 2016. PMID: 27852824 Free PMC article.
-
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.J Natl Cancer Inst. 2002 Jun 5;94(11):819-25. doi: 10.1093/jnci/94.11.819. J Natl Cancer Inst. 2002. PMID: 12048269
-
Molecular control of lymphatic metastasis.Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Ann N Y Acad Sci. 2008. PMID: 18519975 Review.
-
Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.Int J Oncol. 2005 Sep;27(3):669-79. Int J Oncol. 2005. PMID: 16077915
-
[Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer].Ai Zheng. 2009 Dec;28(12):1337-43. doi: 10.5732/cjc.009.10070. Ai Zheng. 2009. PMID: 19958632 Review. Chinese.
Cited by
-
Potential therapeutic strategies for lymphatic metastasis.Microvasc Res. 2007 Sep-Nov;74(2-3):145-58. doi: 10.1016/j.mvr.2007.08.006. Epub 2007 Sep 19. Microvasc Res. 2007. PMID: 17950368 Free PMC article. Review.
-
Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives.Signal Transduct Target Ther. 2025 May 19;10(1):170. doi: 10.1038/s41392-025-02249-0. Signal Transduct Target Ther. 2025. PMID: 40383803 Free PMC article. Review.
-
Th2 Cytokines IL-4, IL-13, and IL-10 Promote Differentiation of Pro-Lymphatic Progenitors Derived from Bone Marrow Myeloid Precursors.Stem Cells Dev. 2022 Jun;31(11-12):322-333. doi: 10.1089/scd.2022.0004. Epub 2022 May 23. Stem Cells Dev. 2022. PMID: 35442077 Free PMC article.
-
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.J Transl Med. 2011 Jul 25;9:120. doi: 10.1186/1479-5876-9-120. J Transl Med. 2011. PMID: 21787417 Free PMC article. Clinical Trial.
-
Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors.Int J Mol Sci. 2023 Aug 28;24(17):13317. doi: 10.3390/ijms241713317. Int J Mol Sci. 2023. PMID: 37686121 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous